Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹8 Cr
Revenue (TTM)
₹143 Cr
Net Profit (TTM)
₹-307 Cr
ROE
-328.5 %
ROCE
-16 %
P/E Ratio
--
P/B Ratio
-0
Industry P/E
44.74
EV/EBITDA
-16.8
Div. Yield
0 %
Debt to Equity
-17.1
Book Value
₹--
EPS
₹-127.9
Face value
10
Shares outstanding
19,341,590
CFO
₹907.61 Cr
EBITDA
₹654.00 Cr
Net Profit
₹-133.86 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ankur Drugs & Pharma
| -70.9 | -8.8 | -41.1 | -70.8 | -70.8 | -56.4 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Healthcare#
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ankur Drugs & Pharma
|
3.7 | 7.6 | 142.8 | -247.4 | -92.9 | -100 | -- | 0.0 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Manufacture of allopathic pharmaceutical preparations
Incorporated
1995
Chairman
Purnandu Jain
Managing Director
Purnandu Jain
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Ankur Drugs & Pharma Ltd is ₹3.65 (NSE) and ₹3.93 (BSE) as of 10-Sep-2013 IST. Ankur Drugs & Pharma Ltd has given a return of -70.76% in the last 3 years.
Since, TTM earnings of Ankur Drugs & Pharma Ltd is negative, P/E ratio is not available.
The P/B ratio of Ankur Drugs & Pharma Ltd is -0.04 times as on 05-Sep-2013, a 101 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2012
|
0.00
|
-0.49
|
|
2011
|
0.00
|
0.41
|
|
2010
|
4.54
|
1.23
|
|
2009
|
3.46
|
0.49
|
|
2008
|
3.62
|
1.09
|
The 52-week high and low of Ankur Drugs & Pharma Ltd are Rs -- and Rs -- as of 05-Apr-2026.
Ankur Drugs & Pharma Ltd has a market capitalisation of ₹ 8 Cr as on 05-Sep-2013. As per SEBI classification, it is a company.
Before investing in Ankur Drugs & Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.15
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.